Karmanos Cancer Institute Adopts UroNav Technology to Diagnose Prostate Cancer

Karmanos Cancer Institute Adopts UroNav Technology to Diagnose Prostate Cancer
Urologists at Detroit's Barbara Ann Karmanos Cancer Institute have switched to a more sophisticated technology for diagnosing prostate cancer: the UroNav Fusion Biopsy System. UroNav fuses 3D magnetic resonance imaging (MRI) pictures of the prostate with live ultrasound images to guide the biopsy procedure. The machine fuses images so they move and change in real time as urologists perform biopsies. "An MRI is better at seeing tumors in the prostate," Michael Cher, MD, chair of urology at Karmanos, said in a press release. “MRI images are highly detailed, and our radiologists are experts at finding tumors on the images. With this new MRI-ultrasound image fusion system, our urologists are able to biopsy suspicious MRI-detected areas while doing live ultrasound.” UroNav is recommended for men with elevated prostate-specific antigen (PSA) test results and who have never undergone a prostate biopsy, for men with a diagnosis of a small prostate cancer for whom active surveillance is an option, or for men who are already on active surveillance for several years (in which case doctors use UroNav to detect tumor progression). Demand for this system is growing rapidly, said Cher, one of nearly 300 physicians and researchers on faculty at Wayne State University School of Medicine. WSU has a long-term partnership with Karmanos, which is a subsidiary of McLaren Health Care and is one of
Subscribe or to access all post and page content.

One comment

  1. Chris O'Neill says:

    “We are better at finding cancers, and therefore better at determining the best treatment plan for each patient.”

    Doesn’t necessarily follow. PSA screening leads to finding lots of cancers but doesn’t save lives overall, not even from prostate cancer itself outside Sweden or the Netherlands. There needs to be a randomised controlled trial before anyone can claim a better outcome.

Leave a Comment

Your email address will not be published. Required fields are marked *